Petrochemical Group announced its annual results for the year ended 31 December 2023, with total revenues of RMB314.50 billion, an increase of 1.7% compared to 2022. Pharmaceutical revenues grew by 4.6%, while revenues from other businesses such as raw materials and functional foods decreased by 9.7% and 8.9%, respectively. Shareholders accounted for a profit of RMB58.73 billion, down 3.6% year-on-year. Basic earnings per share were RMB52.86, an increase of 3.2% year-on-year. The Board of Directors proposes a final dividend of HK14 cents per share, with a full-year dividend of HK$28 cents per share, an increase of 33.3% compared to 2022. The Petropharmaceutical Group actively expands the international market and continues to increase R&D investments, with R&D expenses of RMB48.30 billion, accounting for 18.8% of the revenue of the pharmaceutical business. The Company repurchased and written off 30,000,000 shares during the year to improve earnings per share and return to shareholders.

Petrochemical Group announced its annual results for the year ended 31 December 2023, with total revenues of RMB314.50 billion, an increase of 1.7% compared to 2022. Pharmaceutical revenues grew by 4.6%, while revenues from other businesses such as raw materials and functional foods decreased by 9.7% and 8.9%, respectively. Shareholders accounted for a profit of RMB58.73 billion, down 3.6% year-on-year. Basic earnings per share were RMB52.86, an increase of 3.2% year-on-year. The Board of Directors proposes a final dividend of HK14 cents per share, with a full-year dividend of HK$28 cents per share, an increase of 33.3% compared to 2022. The Petropharmaceutical Group actively expands the international market and continues to increase R&D investments, with R&D expenses of RMB48.30 billion, accounting for 18.8% of the revenue of the pharmaceutical business. The Company repurchased and written off 30,000,000 shares during the year to improve earnings per share and return to shareholders.